Hyperhomocysteinemia is common in patients with antiphospholipid syndrome and may contribute to expression of major thrombotic events

被引：17

作者：

Avivi, I

Lanir, N

Hoffman, R

Brenner, B ^{[1
]}

机构：

[1] Rambam Med Ctr, Dept Hematol, Thrombosis & Hemostasis Unit, IL-31096 Haifa, Israel

[2] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel

来源：

BLOOD COAGULATION & FIBRINOLYSIS | 2002年 / 13卷 / 02期

关键词：

antiphospholipid syndrome; hyperhomocysteinemia; thromboembolism;

D O I：

10.1097/00001721-200203000-00013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Homocysteine plasma levels were measured by high-performance liquid chromatography in 52 patients with primary antiphospholipid syndrome (APS). Elevated homocysteine concentrations (greater than or equal to 15 mumol/1) were found in 16/52 (30.8%) APS patients. Elevated homocysteine levels were found to be associated with an increased risk for a major thromboembolic event (50 versus 16.7%, P = 0.014). Hyperhomocysteinemia is a common finding in APS patients, and may contribute to severity of thrombotic tendency observed in this syndrome. Blood Coagul Fibrinolysis 13:169-172 (C) 2002 Lippincott Williams Wilkins.

引用

收藏

页码：169 / 172

页数：4

相关论文

共 15 条

[1] INCREASED THROMBOXANE FORMATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME [J].

ARFORS, L ;

VESTERQVIST, O ;

JOHNSSON, H ;

GREEN, K .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (06) :607-612

[2] Tissue factor pathway inhibitor levels in patients with homocystinuria [J].

Cella, G ;

Burlina, A ;

Sbarai, A ;

Motta, G ;

Girolami, A ;

Berrettini, M ;

Strauss, W .

THROMBOSIS RESEARCH, 2000, 98 (05) :375-381

[3]

DAngelo A, 1997, BLOOD, V90, P1

[4] THE CATALYTIC ROLE OF ANIONIC PHOSPHOLIPIDS IN THE ACTIVATION OF PROTEIN-C BY FACTOR-XA AND EXPRESSION OF ITS ANTICOAGULANT FUNCTION IN HUMAN PLASMA [J].

FREYSSINET, JM ;

TOTIORFANOUDAKIS, F ;

RAVANAT, C ;

GRUNEBAUM, L ;

GAUCHY, J ;

CAZENAVE, JP ;

WIESEL, ML .

BLOOD COAGULATION & FIBRINOLYSIS, 1991, 2 (06) :691-698

[5] Guidelines on the investigation and management of the antiphospholipid syndrome [J].

Greaves, M ;

Cohen, H ;

Machin, SJ ;

Mackie, I .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) :704-715

[6] INHIBITION OF THROMBOMODULIN SURFACE EXPRESSION AND PROTEIN-C ACTIVATION BY THE THROMBOGENIC AGENT HOMOCYSTEINE [J].

LENTZ, SR ;

SADLER, JE .

JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (06) :1906-1914

[7] Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus [J].

Petri, M ;

Roubenoff, R ;

Dallal, GE ;

Nadeau, MR ;

Selhub, J ;

Rosenberg, IR .

LANCET, 1996, 348 (9035) :1120-1124

[8] Pathogenesis and treatment of the antiphospholipid antibody syndrome [J].

Petri, M .

MEDICAL CLINICS OF NORTH AMERICA, 1997, 81 (01) :151-+

[9] Biological and environmental determinants of plasma homocysteine [J].

Schneede, J ;

Refsum, H ;

Ueland, PM .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (03) :263-279

[10] ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE CONCENTRATIONS AND EXTRACRANIAL CAROTID-ARTERY STENOSIS [J].

SELHUB, J ;

JACQUES, PF ;

BOSTOM, AG ;

DAGOSTINO, RB ;

WILSON, PWF ;

BELANGER, AJ ;

OLEARY, DH ;

WOLF, PA ;

SCHAEFER, EJ ;

ROSENBERG, IH .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (05) :286-291